J&J drug shows promise in high-risk prostate cancer
<p><a href="http://news.yahoo.com/j-j-drug-shows-promise-high-risk-prostate-035351162--finance.html"><img src="http://l.yimg.com/bt/api/res/1.2/FSEHnc1VoYYbooZEWgIDRg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-05-17T035351Z_1_CBRE84F1UCL00_RTROPTP_2_JOHNSONANDJOHNSON.JPG" width="130" height="86" alt="A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster" align="left" title="A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster" border="0" /></a>(Reuters) - Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease. The mid-stage trial found that six months of treatment with the combination therapy completely or nearly eliminated the cancer in a third of patients, all of whom had localized, aggressive cancer. ...</p><br clear="all"/>
Advanced Prostate Cancer Drug May Help at Earlier Stage
WEDNESDAY, May 16 (HealthDay News) -- A drug approved to treat advanced prostate cancer appears to help men who have localized high-risk prostate cancer if given before surgery.
Dinosaurs May Have Suffered From Arthritis
WEDNESDAY, May 16 (HealthDay News) -- Dinosaurs may have suffered from arthritis, new research says.
Array shares rise on lung cancer, melanoma results
(Reuters) - Array BioPharma Inc's experimental lung cancer drug, selumetinib, w as shown to increase survival by an additional 4.2 months over chemotherapy alone, according to new data released on Wednesday. The company also reported encouraging results of a new melanoma treatment, and its shares rose 5 percent after-hours. Array, which has licensed the lung cancer drug to AstraZeneca Plc, announced last year that a mid-stage trial had failed to meet its main goal of showing statistically significant improvement in overall survival. ...
J&J drug shows promise in high-risk prostate cancer
<p><a href="http://news.yahoo.com/j-j-drug-shows-promise-high-risk-prostate-220144591--finance.html"><img src="http://l2.yimg.com/bt/api/res/1.2/PbOWbxK6WxwMl8srPVIKJQ--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-05-16T235302Z_1_CBRE84F1UCL00_RTROPTP_2_JOHNSONANDJOHNSON.JPG" width="130" height="86" alt="A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster" align="left" title="A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster" border="0" /></a>(Reuters) - Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease. The mid-stage trial found that six months of treatment with the combination therapy completely or nearly eliminated the cancer in a third of patients, all of whom had localized, aggressive cancer. ...</p><br clear="all"/>
Aveo kidney cancer drug more tolerated than Nexavar
(Reuters) - Patients taking a kidney cancer drug being developed by Aveo Pharmaceuticals Inc were half as likely to need a break from the medication due to side effects than those on the widely used medicine Nexavar, according to data released on Wednesday. There were also significantly fewer patients taking Aveo's tivozanib who required a dose reduction than those on Nexavar. ...
Study links vets to brain disease seen in athletes
A small study raises more concern about the long-term consequences of brain injuries suffered by thousands of soldiers — suggesting they may be at risk of developing the same degenerative brain disease as some retired football players.
Back pain tends to improve quickly, not completely
NEW YORK (Reuters Health) - Lower back pain often fades fairly quickly, but it may stubbornly linger to some extent for months or more, a new study finds. "The clear good news is that if you seek care for your back pain, you do improve pretty quickly, and some folk do a lot better than others," said Christopher G. Maher, at researcher at the George Institute for Global Health in Sydney, Australia, who worked on the study. The less-than-good news is that, on average, people with low back pain tend to still have some symptoms as much as a year later. ...
|
